Mutations in HIV-1 Genomes from Patients Treated with KP1461
Author Information
Author(s): Mullins James I., Heath Laura, Hughes James P., Kicha Jessica, Styrchak Sheila, Wong Kim G., Rao Ushnal, Hansen Alexis, Harris Kevin S., Laurent Jean-Pierre, Li Deyu, Simpson Jeffrey H., Essigmann John M., Loeb Lawrence A., Parkins Jeffrey
Primary Institution: University of Washington, School of Medicine
Hypothesis
Can the mutagenic nucleoside KP1461 increase mutation rates in HIV-1 genomes to collapse the viral population?
Conclusion
The study found that while KP1461 did not reduce plasma viral loads, it did increase the number of private mutations in treated individuals compared to controls.
Supporting Evidence
- The study analyzed over 7.1 million base pairs of unique HIV-1 genomes.
- Private mutations increased significantly in treated individuals after 56 and 124 days.
- The mutation spectrum showed an excess of A to G and G to A mutations as predicted.
Takeaway
Researchers gave a medicine called KP1461 to people with HIV to see if it could make the virus change so much that it would stop growing. They found that it did make some changes, but not enough to make the virus go away.
Methodology
The study analyzed viral sequences from HIV-1 infected volunteers treated with KP1461 for 124 days, comparing them to untreated controls.
Potential Biases
The absence of a placebo group may introduce bias in interpreting the results.
Limitations
The study duration was short, and no sustained reduction in viral load was observed.
Participant Demographics
Participants were HIV-1 infected individuals with a median of 15.5 years since diagnosis, all ART-experienced.
Statistical Information
P-Value
p=0.002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website